vimarsana.com

Latest Breaking News On - Senior clinical development - Page 1 : vimarsana.com

REGENXBIO Announces Presentations at the 19th Annual WORLDSymposium™ 2023

Nouscom Strengthens Leadership Team with the Appointments of Sven Gogov, MD, as Chief Medical Officer and Maria Arce-Tomas, PhD, as VP, Head of Regulatory Affairs

REGENXBIO Announces Presentations at the 18th Annual WORLDSymposium™ 2022

/PRNewswire/ Interim data from Phase I/II trials of RGX-121 for the treatment of MPS II and RGX-111 for the treatment of MPS I to be presented REGENXBIO Inc..

Objective Acuity announces successful pilot study in children with CLN2 Batten disease

Objective Acuity announces successful pilot study in children with CLN2 Batten disease News provided by Share this article AUCKLAND, New Zealand, May 10, 2021 /PRNewswire/  Objective Acuity ( OAL ) today announced the completion of a pilot study using OAL s threshold visual acuity test for young children diagnosed with late-infantile neuronal ceroid lipofuscinosis Type 2 (CLN2 disease), a form of Batten disease. A prominent feature of CLN2 disease is vision loss, which typically develops when cognitive, motor and language impairments are already present. Measurement of visual acuity of those with the disease using standard methods is difficult and unreliable due to the age of those affected and their cognitive, language, and motor impairments.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.